• 8:30 - 18:00 M-T / 8.30 - 15.00 F

HC016 Acute Lung Injury


The HC016 platform is a treatment of acute lung injury, based on mesenchymal stem cells derived from adipose tissue (ASC), improved with proprietary Histocell technology.
hc016-lung

Development stage

"In vivo" Poc study finished with promising results.

"In vivo" Safety regulatory study finished with good safety profile.

Phase I/II clinical trial for Acute Respiratory Distress Syndrome (ARDS) was approved by the Spanish Agency of Medicines and Medical Devices in December 2019.

Phase I: Dose escalating Phase I study in 6 patients with moderate to severe ARDS inluded in 2 sequential cohorts.

Phase II: Randomised, controlled, double-blind. 20 patients with moderate to severe ARDS divided into 2 groups (treated and control).

Recruiting starts: Q2 2020.

Histocell

Histocell, S.L.
Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900
info@histocell.com
www.histocell.com

Our mission

We develop new healthcare products and cell therapy drugs to improve people's quality of life.

Copyright © Histocell